Vaccinex, Inc

(NASDAQ:VCNX)

Latest On Vaccinex, Inc (VCNX):

Date/Time Type Description Signal Details
2023-05-16 05:44 ESTNewsVaccinex GAAP EPS of -$0.10, revenue of $0.55MN/A
2023-04-03 10:59 ESTNewsVaccinex GAAP EPS of -$0.47, revenue of $0.28MN/A
2023-04-03 10:59 ESTNewsVaccinex announces private placement with commitments of $5MN/A
2023-03-22 02:50 ESTNewsVaccinex starts trial of pepinemab, Bavencio combo to treat pancreatic cancerN/A
2022-11-28 19:44 ESTNewsVaccinex raises $3.8M in direct stock offeringN/A
2022-11-14 16:50 ESTNewsVaccinex GAAP EPS of -$0.11, revenue of $0.05MN/A
2022-08-15 23:13 ESTNewsVaccinex GAAP EPS of -$0.13N/A
2022-05-16 21:55 ESTNewsVaccinex GAAP EPS of -$0.12N/A
2022-03-31 20:51 ESTNewsVaccinex GAAP EPS of -$0.78, revenue of $0.9MN/A
2022-01-27 22:14 ESTNewsVaccinex surges on $6.6M private placementN/A
2022-01-26 12:29 ESTNewsVaccinex stock jumps 24% on positive pepinemab + Keytruda data in head/neck cancer studyN/A
2022-01-04 19:51 ESTNewsVaccinex/Merck reports interim data from Phase Ib KEYNOTE B84 combo study in head and neck cancerN/A
2021-11-08 20:54 ESTNewsVaccinex reports Q3 resultsN/A
2021-08-17 02:50 ESTNewsVaccinex EPS beats by $0.08N/A
2021-07-22 07:08 ESTNewsVaccinex (VCNX) Presents At 2021 Global Healthcare Virtual Conference - SlideshowN/A
2021-07-22 07:04 ESTNewsVaccinex provides site activation update for pepinemab trialsN/A
2021-04-22 03:16 ESTNewsVaccinex's pepinemab combo study shows encouraging activity in lung cancerN/A
2021-03-17 11:02 ESTNewsVaccinex beats on revenueN/A
2021-03-02 02:35 ESTNewsVaccinex: Still Gets An 'Incomplete' GradingN/A
2021-02-23 04:34 ESTNewsVaccinex announces licensing deal with Surface OncologyN/A
2021-02-19 18:00 ESTNewsVaccinex doubles on signing of two multi-project dealsN/A
2020-11-26 21:55 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 13:43 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 13:04 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 12:37 ESTNewsVaccinex EPS misses by $0.01N/A
2020-11-08 01:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:29 ESTFinancialsCompany financials have been released.Neutral
2020-09-28 05:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $21 to $13.5.Neutral
2020-09-26 14:28 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 05:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.33 to $21.Neutral
2020-09-22 11:28 ESTNewsVaccinex lead candidate flunks Huntington's study, shares crater 59%N/A
2020-09-17 08:52 ESTNewsVaccinex partners with Merck in cancerN/A
2020-09-17 06:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-03 16:42 ESTInsider TradeScott E. Royer has directly acquired 500 shares and currently holds 4,499 shares.Buy
2020-08-16 09:55 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 07:41 ESTNewsVaccinex EPS beats by $0.12N/A
2020-08-14 10:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 09:50 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 06:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 22:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 16:48 ESTInsider TradeJohn E. Leonard has directly acquired 1,000 shares and currently holds 1,000 shares.Buy
2020-07-27 14:06 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-15 20:08 ESTInsider TradeALBERT FRIEDBERG has acquired 1,126,760 shares indirectly via Friedberg Global-Macro Hedge Fund Ltd..Buy
2020-07-14 23:30 ESTNewsVaccinex adds to rally ahead of expected readout from Huntington's studyN/A
2020-07-09 10:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 18:08 ESTNewsVersatile Vaccinex Needs A Trial Or Partner Win, But Scaled Down Operation May Be More LikelyN/A
2020-07-01 18:05 ESTFinancialsCompany financials have been released.Neutral

About Vaccinex, Inc (VCNX):

Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

VCNX Quotes by TradingView

See Advanced Chart

General

  • Name Vaccinex, Inc
  • Symbol VCNX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 45
  • Fiscal Year EndDecember
  • IPO Date2018-08-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.vaccinex.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1212.43
  • Enterprise Value Revenue 1445.93
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.34
  • Operating Margin -4573%
  • Return on Assets -121%
  • Return on Equity -748%
  • Revenue 625000
  • Earnings Per Share -$3.01
  • Revenue Per Share $0.04
  • Gross Profit 324000
  • Quarterly Earnings Growth 54.7%
View More

Highlights

  • Market Capitalization 77.23 million
  • EBITDA -32785000
  • PE Ratio -0.36
  • Analyst Target Price $13.5
  • Book Value Per Share -$2.30
View More

Share Statistics

  • Shares Outstanding 22.39 million
  • Shares Float 10.61 million
  • % Held by Insiders 1840%
  • % Held by Institutions 50.4%
  • Shares Short 889420
  • Shares Short Prior Month 627445
  • Short Ratio 0.06
  • Short % of Float 7%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.9
  • 52 Week High $9.4
  • 52 Week Low $1.63
  • 50 Day Moving Average 3.31
  • 200 Day Moving Average 2.74
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Vaccinex, Inc (VCNX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Vaccinex, Inc (VCNX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.44-$0.44-1.15%
2020-06-302020-08-14$N/A-$0.39-$0.5123.53%
2020-03-312020-05-14$N/A-$0.45-$0.7540%
2019-12-312020-03-09$N/A-$0.38-$0.5834.48%
2019-09-302019-11-12$404000-$0.56-$0.6615.15%
2019-06-302019-08-14$25000-$0.77-$0.70-10%
2019-03-312019-05-15$94000-$0.79-$0.71-12.06%
2018-12-312019-03-13$194000-$0.74-$0.807.42%
2018-09-302018-11-13$198000-$0.58-$0.627.26%
2018-06-302018-08-10$126000-$0.65

Vaccinex, Inc (VCNX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Vaccinex, Inc (VCNX) Chart:

Vaccinex, Inc (VCNX) News:

Below you will find a list of latest news for Vaccinex, Inc (VCNX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Vaccinex, Inc (VCNX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest VCNX Trades:

Date Shares Price
Jun 13, 2022 7:56 PM EST100$1.175
Jun 13, 2022 7:56 PM EST100$1.175
Jun 13, 2022 7:57 PM EST6$1.175
Jun 13, 2022 7:58 PM EST3$1.17
Jun 13, 2022 7:58 PM EST100$1.17

Vaccinex, Inc (VCNX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000205/0000891839-20-000205-index.htm
2020-02-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1205922/000000000020001533/0000000000-20-001533-index.htm
2020-03-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1205922/000000000020002211/0000000000-20-002211-index.htm
2020-08-20UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1205922/000000000020007746/0000000000-20-007746-index.htm
2020-08-20UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1205922/000000000020007747/0000000000-20-007747-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1747866/000089183919000038/0000891839-19-000038-index.htm
2019-03-184/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1747866/000089183919000042/0000891839-19-000042-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000032/0000891839-20-000032-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000033/0000891839-20-000033-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000034/0000891839-20-000034-index.htm
2020-02-103/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000038/0000891839-20-000038-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000050/0000891839-20-000050-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000051/0000891839-20-000051-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000052/0000891839-20-000052-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000053/0000891839-20-000053-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000054/0000891839-20-000054-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000075/0000891839-20-000075-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000078/0000891839-20-000078-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000079/0000891839-20-000079-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000083/0000891839-20-000083-index.htm
2020-03-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000084/0000891839-20-000084-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000086/0000891839-20-000086-index.htm
2020-05-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000116/0000891839-20-000116-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000117/0000891839-20-000117-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000118/0000891839-20-000118-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000119/0000891839-20-000119-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000120/0000891839-20-000120-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000121/0000891839-20-000121-index.htm
2020-05-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000122/0000891839-20-000122-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000205/0000891839-20-000205-index.htm
2020-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000208/0000891839-20-000208-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000213/0000891839-20-000213-index.htm
2020-07-284/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000214/0000891839-20-000214-index.htm
2020-09-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000253/0000891839-20-000253-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000254/0000891839-20-000254-index.htm
2020-09-034/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000255/0000891839-20-000255-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000256/0000891839-20-000256-index.htm
2020-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000089183920000296/0000891839-20-000296-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1205922/000089914020000338/0000899140-20-000338-index.htm
2020-01-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1205922/000101905620000029/0001019056-20-000029-index.htm
2020-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1205922/000101905620000418/0001019056-20-000418-index.htm
2020-10-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1205922/000110465920115880/0001104659-20-115880-index.htm
2018-08-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1747866/000112329218000910/0001123292-18-000910-index.htm
2018-08-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1747866/000112329218000926/0001123292-18-000926-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000112329220000631/0001123292-20-000631-index.htm
2020-02-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1205922/000119312520035616/0001193125-20-035616-index.htm
2020-02-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1205922/000119312520035658/0001193125-20-035658-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520050123/0001193125-20-050123-index.htm
2020-03-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1205922/000119312520067341/0001193125-20-067341-index.htm
2020-03-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1205922/000119312520067342/0001193125-20-067342-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1205922/000119312520088913/0001193125-20-088913-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1205922/000119312520088935/0001193125-20-088935-index.htm
2020-04-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1205922/000119312520101408/0001193125-20-101408-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520144556/0001193125-20-144556-index.htm
2020-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520190745/0001193125-20-190745-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520205401/0001193125-20-205401-index.htm
2020-08-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1205922/000119312520220385/0001193125-20-220385-index.htm
2020-08-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1205922/000119312520220395/0001193125-20-220395-index.htm
2020-08-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1205922/000119312520220408/0001193125-20-220408-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520220425/0001193125-20-220425-index.htm
2020-08-21S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1205922/000119312520226994/0001193125-20-226994-index.htm
2020-08-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1205922/000119312520227000/0001193125-20-227000-index.htm
2020-08-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1205922/000119312520227003/0001193125-20-227003-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520232105/0001193125-20-232105-index.htm
2020-09-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1205922/000119312520242246/0001193125-20-242246-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520242257/0001193125-20-242257-index.htm
2020-09-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520250645/0001193125-20-250645-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1205922/000119312520276927/0001193125-20-276927-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1205922/000156459020009251/0001564590-20-009251-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1205922/000156459020025279/0001564590-20-025279-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1205922/000156459020040174/0001564590-20-040174-index.htm
2020-02-03DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000156761920001927/0001567619-20-001927-index.htm
2020-07-15DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000156761920013306/0001567619-20-013306-index.htm
2020-08-11DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000156761920014734/0001567619-20-014734-index.htm
2020-09-16DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1205922/000156761920016794/0001567619-20-016794-index.htm
2020-03-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1205922/999999999520000551/9999999995-20-000551-index.htm
2020-03-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1205922/999999999520000552/9999999995-20-000552-index.htm
2020-08-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1205922/999999999520002254/9999999995-20-002254-index.htm
2020-08-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1205922/999999999520002255/9999999995-20-002255-index.htm

Vaccinex, Inc (VCNX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vaccinex, Inc (VCNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1840%
Institutional Ownership: 5040%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-27John E. LeonardSVP, DevelopmentBuy1,000.003.903,900.001,000.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000213/0000891839-20-000213-index.htm
2020-01-23Maurice ZaudererPresident and CEOBuy98,231.005.09499,995.791,097,753.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000032/0000891839-20-000032-index.htm
2020-07-10ALBERT FRIEDBERGDirectorBuy1,126,760.003.553,999,998.001,710,093.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000208/0000891839-20-000208-index.htm
2020-01-23Jacob B. FriebergDirectorBuy39,292.005.09199,996.2839,292.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000033/0000891839-20-000033-index.htm
2020-09-03Scott E. RoyerChief Financial OfficerBuy500.003.901,950.004,499.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000256/0000891839-20-000256-index.htm
2019-03-14ALBERT FRIEDBERGDirectorBuy1,000.004.004,000.004,789,469.00https://www.sec.gov/Archives/edgar/data/1747866/000089183919000038/0000891839-19-000038-index.htm
2019-03-15ALBERT FRIEDBERGDirectorBuy1,000.003.963,960.004,790,469.00https://www.sec.gov/Archives/edgar/data/1747866/000089183919000038/0000891839-19-000038-index.htm
2020-01-23ALBERT FRIEDBERGDirectorBuy982,318.005.094,999,998.627,601,330.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000034/0000891839-20-000034-index.htm
2020-03-09ALBERT FRIEDBERGDirectorBuy231.004.22974.827,601,561.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000075/0000891839-20-000075-index.htm
2020-03-10ALBERT FRIEDBERGDirectorBuy4,000.004.2016,800.007,605,561.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000075/0000891839-20-000075-index.htm
2020-03-13ALBERT FRIEDBERGDirectorBuy3,000.004.2812,840.007,608,561.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000078/0000891839-20-000078-index.htm
2020-03-16ALBERT FRIEDBERGDirectorBuy600.004.152,490.007,609,161.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000078/0000891839-20-000078-index.htm
2020-03-17ALBERT FRIEDBERGDirectorBuy3,440.004.0013,760.007,612,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000078/0000891839-20-000078-index.htm
2020-03-19ALBERT FRIEDBERGDirectorBuy4,000.004.1516,600.007,616,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000079/0000891839-20-000079-index.htm
2020-03-20ALBERT FRIEDBERGDirectorBuy2,000.004.318,620.007,618,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000079/0000891839-20-000079-index.htm
2020-03-24ALBERT FRIEDBERGDirectorBuy2,000.004.408,800.007,620,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000083/0000891839-20-000083-index.htm
2020-03-26ALBERT FRIEDBERGDirectorBuy1,000.004.444,440.007,621,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000083/0000891839-20-000083-index.htm
2020-03-27ALBERT FRIEDBERGDirectorBuy4,000.004.1816,720.007,625,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000084/0000891839-20-000084-index.htm
2020-03-30ALBERT FRIEDBERGDirectorBuy5,000.004.0620,300.007,630,601.00https://www.sec.gov/Archives/edgar/data/1205922/000089183920000084/0000891839-20-000084-index.htm